• Mustafa Egla AL-Habboobi General Hospital, Thi-qar Health Directorate, Ministry of Health, Thi-qar, Iraq
  • Shaimaa N. Abd Al Hammid Department of Pharmaceutics, College of pharmacy, University of Baghdad, Baghdad, Iraq



Orodispersible tablet, Zolmitriptan, Liquisolid technique


Objective: The objective of present study is to develop orodispersible tablets (ODTs) of zolmitriptan by liquisolid technique using different types of super disintegrants to enhance the disintegration and dissolution of zolmitriptan to improve the bioavailability of the drug.

Methods: Liquisolid ODTs of zolmitriptan were prepared from; microcrystalline cellulose (Avicel PH-102) as carrier, colloidal silicon dioxide (Aerosil 200) as a coating material, croscarmellose sodium (CSS), sodium starch glycolate (SSG), and crospovidone (CP) as super disintegrants, and propylene glycol as liquid vehicle. The ratio of carrier to coating material was kept constant in all formulations at 35:1, this ratio was chosen after testing the ratios 10:1, 15:1, 20:1, 25:1,30:1, and 35:1. The ratio 35:1 give optimal results relative to other ratios. The pre-compression evaluation includes: flow properties were measured using the angle of repose and the compressibility index and FT-IR. The prepared liquid-solid system compacts were evaluated for their post-compression evaluation which includes: hardness, friability, wetting time, in vitro disintegration time, drug content and in vitro drug release.

Results: The tabletting properties of the liquid-solid ODTs were within the acceptable limits. Among the three super disintegrants, CP found to be the best in term of showing the fastest disintegration time. The optimized selected formula (F11) was prepared using 5% w/w crospovidone, by direct compression showed the shortest disintegration time (24 s), superior drug release profile [ the time required for 80% of the drug to be released (T80%) and percent drug dissolved in 2 min (D2 min) 1.84 min and 87.59%, respectively]. In addition to that, the selected formula had an acceptable hardness and friability, so it was selected as the best formula.

Conclusion: The overall results showed that CP was the best super disintegrant of showing the shortest disintegration time while loading factor of 0.125 was the best in the preparing of zolmitriptan liquid-solid ODTs, and this suggested the possibility of utilizing the selected best formula (F11) in the preparation of zolmitriptan ODTs as a new dosage form for oral administration. 


Download data is not yet available.


Dressman J, Reppas C. Drug solubility: how to measure it, how to improve it. Adv Drug Delivery Rev 2007;59:531-2.

Kumar VS, Raja C, Jayakumar C. A review on solubility enhancement using hydrotropic phenomena. Int J Pharm Pharm Sci 2014;6:1-7.

Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution, and bioavailability. Asian J Pharm Sci 2014;9:304-16.

Khan I, Khan ML, Khan U. Liquisolid technology: an emerging and advanced technique for enhancing solubilization. Pharm Tutor 2014;2:31-41.

Ganesh NS, Deshpande KB. Orodispersible tablets: an overview of formulation and technology. Int J Pharm Biol Sci 2011;2:726-34.â€

Paul Y, Tyagi S, Singh B. Formulation and evaluation of oral dispersible tablets of zidovudine with different super disintegrants. Int J Curr Pharm Rev Res 2011;2:81-91.

Patil PR, Salve VK, Thorat RU, Shahi SR. Formulation and evaluation of ion-sensitive in-situ nasal gel of zolmitriptan. Int J Pharm Pharm Sci 2015;7:478-86.

Bankim CN, Gupta AK, Mittal A, Mohd KZ. Design and development of solid dispersion system of zolmitriptan. J Biomed Pharm Res 2013;2:7-13.

Azza AM, Salwa S. Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets. Drug Dev Ind Pharm 2012;38:762-9.â€

Altememy DR, Altememy JJ. Formulation and evaluation of meloxicam liquisolid compact. Int J Pharm Pharm Sci 2014;6:453-63.

Spireas S, Bolton M. Liquisolid systems and methods of preparing same. US Patent 1999;5:968, 550.

Elkordy AA, Tan XN, Essa EA. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur J Pharm Biopharm 2013;83:203-23.

Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Dissolution rate enhancement of fenofibrate using liquisolid tablet technique. Lat Am J Pharm 2009;28:219-25.

MM Ghareeb, KK Atiya, JJ Ibraheem. Liquisolid compact as an approach for Tenoxicam solubility enhancement using tween 80 as liquid vehicle. J Chem Pharm Res 2015;7:379-93.

Kaerger S, Edge S, Price R. Influence of particle size and shape on flowability and compactibility of binary mixtures of paracetamol and microcrystalline cellulose. Eur J Pharm Sci 2004;22:173-9.

Parmar K, Patel J, Sheth N. Fabrication and characterization of liquisolid compacts of Embelin for dissolution enhancement. J Pharm Investig 2014;44:391-8.

Malke S, Shidhaye S, Kadam V. Novel melt granulation using sugars for metoclopramide hydrochloride orally disintegrating tablet. Asian J Pharm Clin Res 2009;2:68-72.

Ayalasomayajula LU. Formulation and evaluation of atenolol orodispersible tablets by co-processed super-disintegration process. Int J Adv Pharm 2016;5:46-51.

Bayrak Z, Tas C, Tasdemir U, Erol H, Ozkan CK, Savaser A, et al. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2011;78:499-505.

Patrick H, Jason L, Kenneth SA, Gabriella B. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets. J Pharm Biomed Anal 2016;120:391-6.â€

Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS PharmSciTech 2007;8:127-33.

Brniak W, Jachowicz R, Pelka P. The practical approach to the evaluation of methods used to determine the disintegration time of orally disintegrating tablets (ODTs). Saudi Pharm J 2015;23:437-43.

Salim W, Khalil I. Formulation and evaluation of zolmitriptan bilayers oral strips. World J Pharm Res 2015;4:25-57.

Kopp S. Stability testing of pharmaceutical products in a global environment. Regulatory Affairs J 2006;16:291-4.

Amrit B Karmarkar. Effect of ceolus K G-802 on the dissolution rate of fenofibrate liquisolid tablets: pre-formulation and formulation development studies. Drug Discoveries Ther 2010;4;493-8.

Khanfar M, Sheikh SM, Faiza K. Preparation of the sustained-release dosage form of Venlafaxine HCl using liquisolid technique. Pharm Dev Technol 2014;19:103-15.â€

Singh SK, Prakash D, Srinivasan KK, Gowthamarajan K. Liquisolid compacts of glimepiride: an approach to enhance the dissolution of poorly water soluble drugs. J Pharm Res 2011;4:2263-8.

United States Pharmacopeia. 30ed. Rockville: United States Pharmacopeia Convention; 2008.

Bala R, Khanna S, Pawar P. Polymers in fast disintegrating tablets–a review. Asian J Pharm Clin Res 2012;5:8-14.

Vraníková B, Gajdziok J, Doležel P. The effect of super disintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin. Pharm Dev Technol 2015;23:1-10.

Jagdale SC, Fernandes NC, Kushekar BS, Shah TP, Chabukswar AR. Selection of super disintegrant for Famotidine rapidly disintegrating tablets. J Chem Pharm Res 2010;2:65-72.

Thoorens G, Krier F, Leclercq B, Carlin B, Evrard B. Microcrystalline cellulose, a direct compression binder in quality by design environment-a review. Int J Pharm 2014;473:64-72.

Padmapreetha J, Arulkumaran KSG. Improvement of dissolution rate of diacerein using liquisolid technique. J Chem Pharm Res 2016;8:209-19.

Javadzadeh Y, Shariati H, Movahhed-Danesh E, Nokhodchi A. Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. Drug Dev Ind Pharm 2009;35:243-51.



How to Cite

Egla, M., and S. N. A. A. Hammid. “DESIGN ZOLMITRIPTAN LIQUISOLID ORODISPERSIBLE TABLETS AND THEIR IN VITRO EVALUATION”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 1, Jan. 2017, pp. 297-03, doi:10.22159/ijpps.2017v9i1.15656.



Original Article(s)